The group of companies “R-Pharm” has completed the process of registration of favipiravir (trade name Karanvir) for the treatment of coronavirus infection COVID-19 light and moderate flow. The production of the drug, organized with the participation of industry development Fund, will be implemented by the company “R-Pharm” in Yaroslavl.
This drug was one of the first in Russia and in the world of medicine that fights not with complications caused by SARS-CoV-2, and directly by the virus. The drug inhibits the viral RNA polymerase involved in replication of the virus.
High efficacy has been confirmed through clinical studies conducted in patients with COVID-19 easy and moderate severity that included outpatient and inpatient cohort of patients. According to the findings of the study on the 7th day of therapy, clinical improvement in the group of outpatients was achieved in 55% of participants receiving favipiravir, while in the comparison group, which used the standard etiotropic therapy, improvement was noted only in 20%. Statistically significant difference in this parameter between the groups persisted and on the 14th day of the study.
The use of the drug had a positive influence also on the elimination of the virus SARS-CoV-2: already on the 5th day of elimination occurred in the majority of patients (77,5%) who took the drug. Importantly, the tolerability was good: among the side effects observed, mostly reactions from the gastrointestinal tract and abnormalities of laboratory results in the outpatient population of all side effects were mild.
Immediately after obtaining the registration certificate for the drug will be sent to the regions, and begin to be implemented in hospitals of Moscow, St.-Petersburg, Yaroslavl and other cities.
Previously, the original biotech drug rokyzana developed by the group of companies “R-Pharm” and showed high effectiveness in treating the cytokine storm, was included in the list of recommendations of the Ministry of health for the treatment of complications COVID-19. Integrated application of the national health system of the two drugs, favipiravir and olokizumab, will effectively deal with COVID-19.